For Media
Connect With an Expert
BrightFocus Foundation’s in-house team of scientists are available for media interviews about Alzheimer’s disease, macular degeneration, and glaucoma. To arrange an interview, please contact Julia Roth at jroth@brightfocus.org.

Diane Bovenkamp, PhD
Diane Bovenkamp, PhD, Vice President of Scientific Affairs, is the chief scientist at BrightFocus Foundation, overseeing global operations of the organization’s research programs. She serves as the scientific liaison in local, national, and international forums, and identifies and develops new research initiatives, partnerships, and funding policies consistent with the mission of BrightFocus.
Dr. Bovenkamp obtained her PhD in biochemistry from Queen’s University in Kingston, Ontario, Canada, discovering and studying Eph receptors in angiogenesis and neural development in zebrafish and mice. She completed a postdoctoral fellowship in the Vascular Biology Program at Boston Children’s Hospital/Harvard Medical School, isolating and characterizing zebrafish neuropilins. Dr. Bovenkamp conducted further research at the Johns Hopkins University Bayview Proteomics Center in the Division of Cardiology at Johns Hopkins School of Medicine, using proteomic techniques for biomarker detection in human serum.

Sharyn Rossi, PhD, Director, Neuroscience Programs
Dr. Sharyn Rossi received her PhD in anatomy and neurobiology from the University of California, Irvine, where she studied stem cell replacement therapies for the treatment of spinal cord injury. She continued her post-doctoral work at A.I. duPont Hospital for Children studying spinal muscular atrophy, and Johns Hopkins University, using optogenetics to investigate how transplanted stem cells integrate into brain circuitry after traumatic brain injury. Prior to joining BrightFocus, Dr. Rossi was a senior research scientist at the National Institute on Aging, using neuroimaging, light-sheet microscopy, and novel interventions to investigate changes in the brain during normal cognitive aging.

Preeti Subramanian, PhD, Director, Vision Science Programs
Before joining BrightFocus, Dr. Preeti Subramanian was a research scientist at the National Eye Institute (NEI) of the NIH for 10+ years. Dr. Subramanian received her PhD in biochemistry from Virginia Commonwealth University, where she identified a novel role for bioactive sphingolipid ceramide 1 phosphate (C1P) in mediating inflammation.
She completed her postdoctoral training at the NEI, performing investigations on pigment epithelium-derived factor, an ocular protein with neurotrophic activity. She continued her research in vision science at the NEI, identifying and studying potential therapeutic agents for diseases involving RPE oxidative stress (e.g., age-related macular degeneration).
Latest Research News from BrightFocus-Funded Scientists
BrightFocus Foundation and Focused Ultrasound Foundation Announce Partnership to Advance Alzheimer’s Research
A three-year collaboration supports pioneering non-invasive treatment strategies for Alzheimer’s disease using focused ultrasound.

BrightFocus and Alzheimer’s Los Angeles Renew Partnership to Fund Promising Alzheimer’s Research
Ongoing collaboration advances promising Alzheimer’s drug discovery research in Southern California.
Looking Beyond Pressure-Lowering Drugs to Treat Glaucoma
A National Glaucoma Research-funded scientist is building a 3D model of the optic nerve that she hopes will solve unanswered questions about glaucoma—and inspire new treatments.
Is This the Next Best Thing to Regrowing a New Retina?
A BrightFocus Macular Degeneration Research-funded scientist is investigating a new regeneration technique to restore key cells that are wiped out in late-stage age-related macular degeneration.

New Blood Test Could Personalize Alzheimer’s Treatment Like Never Before
A new Alzheimer’s blood test may reveal how far the disease has progressed and identify who’s most likely to benefit from anti-amyloid therapies.
What Early-Life Brain Activity May Reveal About Alzheimer’s Risk
BrightFocus Alzheimer’s Disease Research grant recipient Keith Hengen, PhD, is pioneering a novel approach to identifying Alzheimer’s risk in early life, which could enable earlier diagnosis, risk reduction, and treatment.
FDA Clears First Blood Test to Aid in Alzheimer’s Diagnosis
The Lumipulse G β-Amyloid Ratio (1-42/1-40) blood test, manufactured by Fujirebio Diagnostics, measures two forms of amyloid-beta in the blood.

BrightFocus Foundation Awards Nearly $13M to 50 Scientists for Alzheimer’s, Macular Degeneration, and Glaucoma Research
Private research nonprofit BrightFocus Foundation today announced nearly $13 million in grants to support early investigative research into Alzheimer’s disease, macular degeneration, and glaucoma.
Does Disrupting the Brain’s Clock Influence Alzheimer’s?
An Alzheimer’s Disease Research-funded researcher is investigating the link between circadian rhythm disruption by jet lag and Alzheimer’s in the hopes of finding new treatment targets.

BrightFocus Foundation and Focused Ultrasound Foundation Announce Partnership to Advance Alzheimer’s Research
A three-year collaboration supports pioneering non-invasive treatment strategies for Alzheimer’s disease using focused ultrasound.

BrightFocus and Alzheimer’s Los Angeles Renew Partnership to Fund Promising Alzheimer’s Research
Ongoing collaboration advances promising Alzheimer’s drug discovery research in Southern California.

Looking Beyond Pressure-Lowering Drugs to Treat Glaucoma
A National Glaucoma Research-funded scientist is building a 3D model of the optic nerve that she hopes will solve unanswered questions about glaucoma—and inspire new treatments.

Is This the Next Best Thing to Regrowing a New Retina?
A BrightFocus Macular Degeneration Research-funded scientist is investigating a new regeneration technique to restore key cells that are wiped out in late-stage age-related macular degeneration.

New Blood Test Could Personalize Alzheimer’s Treatment Like Never Before
A new Alzheimer’s blood test may reveal how far the disease has progressed and identify who’s most likely to benefit from anti-amyloid therapies.

What Early-Life Brain Activity May Reveal About Alzheimer’s Risk
BrightFocus Alzheimer’s Disease Research grant recipient Keith Hengen, PhD, is pioneering a novel approach to identifying Alzheimer’s risk in early life, which could enable earlier diagnosis, risk reduction, and treatment.

FDA Clears First Blood Test to Aid in Alzheimer’s Diagnosis
The Lumipulse G β-Amyloid Ratio (1-42/1-40) blood test, manufactured by Fujirebio Diagnostics, measures two forms of amyloid-beta in the blood.

BrightFocus Foundation Awards Nearly $13M to 50 Scientists for Alzheimer’s, Macular Degeneration, and Glaucoma Research
Private research nonprofit BrightFocus Foundation today announced nearly $13 million in grants to support early investigative research into Alzheimer’s disease, macular degeneration, and glaucoma.

Does Disrupting the Brain’s Clock Influence Alzheimer’s?
An Alzheimer’s Disease Research-funded researcher is investigating the link between circadian rhythm disruption by jet lag and Alzheimer’s in the hopes of finding new treatment targets.
Fact Sheets

Alzheimer’s Disease Facts & Figures
Every three seconds, someone in the world develops dementia. That’s the same amount of time it takes to read this sentence out loud. Get the facts about Alzheimer’s disease—the most common form of dementia.

Macular Degeneration Facts & Figures
Advanced age-related macular degeneration (AMD) is a leading cause of irreversible blindness and visual impairment, affecting nearly 20 million U.S. adults who are living with some form of AMD.

Glaucoma Facts & Figures
More than three million Americans are living with glaucoma, a group of eye disorders that can lead to vision loss or complete blindness.
Press Releases
BrightFocus Foundation and Focused Ultrasound Foundation Announce Partnership to Advance Alzheimer’s Research
A three-year collaboration supports pioneering non-invasive treatment strategies for Alzheimer’s disease using focused ultrasound.

BrightFocus and Alzheimer’s Los Angeles Renew Partnership to Fund Promising Alzheimer’s Research
Ongoing collaboration advances promising Alzheimer’s drug discovery research in Southern California.
BrightFocus Foundation Awards Nearly $13M to 50 Scientists for Alzheimer’s, Macular Degeneration, and Glaucoma Research
Private research nonprofit BrightFocus Foundation today announced nearly $13 million in grants to support early investigative research into Alzheimer’s disease, macular degeneration, and glaucoma.
BrightFocus Foundation and Helen Keller Foundation Award University of Iowa Researchers 2025 Prize for Pioneering Eye Research
Drs. Val C. Sheffield and Edwin M. Stone of the University of Iowa have received the 2025 Helen Keller Prize for Vision Research for their groundbreaking work.

BrightFocus Foundation Recognizes Excellence in Vision Research
The annual BrightFocus Vision Research Awards honor outstanding scientists pursuing groundbreaking macular degeneration and glaucoma research.
BrightFocus Foundation Announces Appointment of Two New Board Members
BrightFocus Foundation, a leading nonprofit funder of innovative research to defeat Alzheimer’s disease, macular degeneration, and glaucoma, has appointed John S. Penn, PhD, a renowned vision scientist and professor at Vanderbilt University Medical Center, and Dale Young, chairman and CEO of Summit Financial Group, to its board of directors.
2024 Research Portfolios Now Available
BrightFocus proudly supports over 200 cutting-edge research grants, fueling the global fight against Alzheimer’s disease, macular degeneration, and glaucoma.

Today’s Investments, Tomorrow’s Breakthroughs: 2024 Annual Report Highlights Scientific Progress
BrightFocus Foundation’s 2024 annual report highlights groundbreaking research and public awareness efforts over the last year to defeat Alzheimer’s disease, macular degeneration, and glaucoma.
BrightFocus Foundation Welcomes Three New Board Members
Global brain and vision research nonprofit BrightFocus Foundation has appointed three industry leaders to its board of directors.

BrightFocus Foundation and Focused Ultrasound Foundation Announce Partnership to Advance Alzheimer’s Research
A three-year collaboration supports pioneering non-invasive treatment strategies for Alzheimer’s disease using focused ultrasound.

BrightFocus and Alzheimer’s Los Angeles Renew Partnership to Fund Promising Alzheimer’s Research
Ongoing collaboration advances promising Alzheimer’s drug discovery research in Southern California.

BrightFocus Foundation Awards Nearly $13M to 50 Scientists for Alzheimer’s, Macular Degeneration, and Glaucoma Research
Private research nonprofit BrightFocus Foundation today announced nearly $13 million in grants to support early investigative research into Alzheimer’s disease, macular degeneration, and glaucoma.

BrightFocus Foundation and Helen Keller Foundation Award University of Iowa Researchers 2025 Prize for Pioneering Eye Research
Drs. Val C. Sheffield and Edwin M. Stone of the University of Iowa have received the 2025 Helen Keller Prize for Vision Research for their groundbreaking work.

BrightFocus Foundation Recognizes Excellence in Vision Research
The annual BrightFocus Vision Research Awards honor outstanding scientists pursuing groundbreaking macular degeneration and glaucoma research.

BrightFocus Foundation Announces Appointment of Two New Board Members
BrightFocus Foundation, a leading nonprofit funder of innovative research to defeat Alzheimer’s disease, macular degeneration, and glaucoma, has appointed John S. Penn, PhD, a renowned vision scientist and professor at Vanderbilt University Medical Center, and Dale Young, chairman and CEO of Summit Financial Group, to its board of directors.

2024 Research Portfolios Now Available
BrightFocus proudly supports over 200 cutting-edge research grants, fueling the global fight against Alzheimer’s disease, macular degeneration, and glaucoma.

Today’s Investments, Tomorrow’s Breakthroughs: 2024 Annual Report Highlights Scientific Progress
BrightFocus Foundation’s 2024 annual report highlights groundbreaking research and public awareness efforts over the last year to defeat Alzheimer’s disease, macular degeneration, and glaucoma.

BrightFocus Foundation Welcomes Three New Board Members
Global brain and vision research nonprofit BrightFocus Foundation has appointed three industry leaders to its board of directors.